Replies to post #133388 on Biotech Values

[vinmantoo]

mcbio,


I just saw the good news!! This is what I have been waiting for as the chronic pain market is the real driver of Relistor sales. I don't think the traders who have been manipulating the stock price will go away, but the lower level of the trading range has been raised. This is a really nice Christmas present for longs, especially those of us who have suffered with PGNX for a very long time.

[ghmm]

SLXP/PGNX: I would like to see the data to better understand it. I am not as familiar with their sub-q product to easily compare with NKTR. The secondary end point is what would be a meaningful comparison. Not saying the data are bad but I don't see any p values or hard numbers (things are very vaguely worded) which would make me cautious if I were long.

I am long NKTR so take my comments with some skepticism if you wish :-)

[mcbio]

SLXP/(PGNX) @ JPM (1/11/12)

Starting just before the 22-minute mark of this presentation, as it relates to PGNX and Relistor, SLXP's CEO states that the current peak-year sales estimate for Relistor (she termed peak-year as being year 7) in its currently approved indication is about $50M. If they gain expanded approval in chronic patients, that peak estimate is $300-$350M. If SLXP/PGNX succeed in gaining approval for oral Relistor, that takes them to a "billion dollar opportunity."